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Transforming growth factor 131 and renal injury following subtotal
nephrectomy in the rat: Role of the renin-angiotensin system. Transform-
ing growth factor-p (TGF-13) and the renin-angiotensin system (RAS)
have both been implicated in the pathogenesis of chronic renal disease.
The present experiment investigated the chronology of TGF-pl gene
expression following subtotal nephrectomy (STNx) in the rat and the effect
of blocking the RAS by angiotensin converting enzyme (ACE) inhibition
or by angiotensin II receptor (AT1) antagonism. Rats that had undergone
subtotal nephrectomy developed hypertension, proteinuria, renal impair-
ment, glomerulosclerosis, tubulointerstitial fibrosis and mononuclear cell
infiltration. These changes were associated with a 2.5-fold increase in
TGF-j31 gene expression during a 16-week time course. In situ hybridiza-
tion localized TGF-131 mRNA to sclerotic glomeruli, areas of tubuloin-
terstitial injury and sites of mononuclear cell infiltration. Administration
of the ACE inhibitor ramipril and the AT1 receptor blocker valsartan
blunted the increase in TGF-1 mRNA, and attenuated the structural and
functional manifestations of injury. These data suggest an interaction
between the intrarenal RAS and TGF-f3 in the pathogenesis of the
glomerular and tubulointerstitial fibrosis that follow a major reduction in
renal mass.
The mechanisms by which glomerular hyperfiltration lead to
progressive glomerulosclerosis, tubulointerstitial scarring and re-
nal impairment are not well understood. Over the past decade the
role of various growth factors in mediating injury has been
intensively studied in glomerular diseases [1] and to a far lesser
extent in disorders of the tubulointerstitium. Considerable exper-
imental evidence supports a key role for transforming growth
factor-13 (TGF-13) in the pathogenesis of several renal diseases
characterized by the accumulation of extracellular matrix [2, 3].
The mechanisms for this prosclerotic action of TGF-f3 are multi-
ple. TGF-p stimulates extracellular matrix (ECM) production by
increasing its synthesis, inhibiting its degradation and modulating
cell-integrin receptors [41. TGF-f3 also attracts mononuclear cells
and stimulates fibroblasts which potentiate the fibrotic process [5].
Subtotal nephrectomy (STNx) provides a well characterized
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model of progressive non-inflammatory glomerulosclerosis ac-
companied by tubulointerstitial injury that eventually leads to
renal failure [61. In addition, the increased single nephron gb-
merular filtration rate and intraglomerular hypertension that
accompany STNx provide a means of exploring the mechanisms
by which disturbed glomerular hemodynamics may lead to gb-
merular and tubulointerstitial fibrosis [7]. The amelioration of
such injury by treatment by angiotensin converting enzyme (ACE)
inhibition [8] and angiotensin II (Ang II) receptor blockade [91
supports the notion of a pathogenetic link between the renin-
angiotensin system and progressive renal injury [10].
The present study sought to examine TGF-pl gene regulation
in both glomeruli and tububointerstitium following STNx and to
determine whether the renoprotective effects of ACE inhibition
and Ang II receptor blockade may be mediated through changes
in TGF-/3 expression.
Methods
Animal model
Experiment 1. To determine the chronology of altered gene
regulation in subtotal nephrectomy a time course experiment was
performed. Sixty male Sprague-Dawley rats weighing 200 to 250
grams were randomly assigned to undergo subtotal (5/6) nephrec-
tomy (STNx, N = 30) or partial (1/6) nephrectomy (PNx, N = 30).
Anesthesia was achieved by the intraperitoneal administration of
pentobarbitone (6 mg/100 g body wt). Subtotal nephrectomy was
performed by right subcapsular nephrectomy and infarction of
approximately two-thirds of the left kidney by selective ligation of
two of three to four extrarenal branches of the left renal artery.
The right kidney excised at this time was decapsulated and used as
a baseline control for histological and molecular biological stud-
ies. Partial nephrectomy (PNx) was performed by the same
surgical procedure except that the right kidney was undisturbed
and only one extrarenal branch of the renal artery was ligated.
Rats were housed in a temperature (22°C) controlled room with
ad libitum access to commercial standard rat chow (Norco,
Lismore, N.S.W., Australia) and water during the entire study.
Ten rats from each group were scheduled for sacrifice at 4, 12 and
16 weeks after surgery. At sacrifice the remnant (left) kidney of
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STNx and the left kidney of PNx animals were excised and the
renal capsule removed.
Experiment 2. To evaluate the effects of the renin-angiotensin
system, a second experiment was performed using the ACE
inhibitor ramipril (Hoechst AG, Frankfurt, Germany) and the
Ang II type 1 (AT1) receptor blocker, valsartan (Ciba-Geigy,
Basel, Switzerland). Forty male Sprague-Dawley rats weighing
200 to 250 grams were randomized to four groups of 10 animals
each. The control group underwent sham surgery consisting of
laparotomy and manipulation of both kidneys before wound
closure (SHAM). The other three groups of rats all underwent
STNx as above and were randomly assigned to STNx alone, STNx
with ramipril (3 mg/liter drinking water) or valsartan (30 mg/kg/
day by gavage) groups. Plasma renin activity was measured by
radioimmunoassay as previously described [11] to confirm that
rats had received appropriate drug treatment. Animals were
sacrificed at 12 weeks. Both experiments 1 and 2 were approved by
the Animal Welfare and Ethics Committee of the Austin and
Repatriation Medical Centre.
Renal function
Body weight was measured weekly. Systolic blood pressure was
measured in conscious rats using an occlusive tail-cuff plethysmo-
graph attached to a pneumatic pulse transducer (Narco Bio-
system, Houston, TX, USA) [12]. Plasma urea and creatinine
were measured by autoanalyzer (Beckman Instruments, Palo
Alto, CA, USA) at entry and at each study point. Glomerular
filtration rate was also measured in experiment 2 by single shot
Tc99mDTPA clearance [13]. Prior to sacrifice, rats were housed in
metabolic cages for 24 hours for measurement of urinary protein
excretion using the Coomassie Brilliant Blue method [14].
Histopathology
Tuhulointerstitial morphology. An 8 mm3 wedge was taken from
the cortex of each kidney at sacrifice and immersion-fixed in 10%
neutral buffered formalin. Paraffin-embedded sections were
stained with hematoxylin and eosin, periodic acid-Schiff (PAS)
and Masson's Trichrome. Morphological analyses were per-
formed with the observer blind to the animal treatment group.
The extent of injury was quantified by a point-counting technique
[15]. Tubulointerstitial changes including normal tubules, dilated
tubules, atrophic tubules, cast, inflammatory cell infiltrates, inter-
stitial fibrosis and overall interstitial spaces (cell infiltrate, fibrosis
and other spaces such as renal vessels and intertubular space)
were quantified on Trichrome-stained sections. Under high power
magnification (x200) light microscopy five random and non-
overlapping fields from each slide were examined using a 121
point graticule to estimate the relative percentage of surface area
occupied by each of the above histological parameters.
Glomerular morphology. Glomerular injury was assessed by
examining 50 glomeruli in PAS-stained sections. Each glomerulus
was graded as either normal [01, mildly sclerotic (1+, lesion
occupying less than 50% of glomerular tuft), severely sclerotic
(2+, lesion occupying more than 50% of glomerular tuft) or
globally sclerotic (3+, lesion occupying 100% of glomerular tuft)
[16]. A semiquantitative score was thus derived for each animal
using the formula:
Score = Fi(i)
where Fi is the percentage of glomeruli in the rat with a given
score i [17].
Immunohistochemistiy
The presence of mononuclear leukocytes was demonstrated
immunohistochemically using the indirect avidin-biotinylated per-
oxidase method as previously described [181. Sections were incu-
bated with a murine monoclonal primary IgG (Serotec, UK)
specific for the monocyte/macrophage antigen, ED1. The immu-
nostaining was quantified by counting the number of positive cells
in twenty glomeruli and twenty grid fields (0.1 mm2) [19]. The
average number of positive cells in each glomerulus and each
interstitial field was then calculated.
Northern blot analysis
At sacrifice or nephrectomy, the kidney was removed and
decapsulated. A block of tissue weighing —400 mg was snap
frozen in liquid nitrogen and stored at —70°C. Tissues were later
homogenized (Ultra-Turrax; Janke and Kunkel, Staufen, Ger-
many) and total RNA isolated by the acid guanidinium thiocya-
nate-phenol-chloroform extraction method [20]. RNA concentra-
tion and purity were determined spectrophotometrically. Twenty
microgram samples were denatured and electrophoresed through
0.8% agarose formaldehyde gels. RNA integrity was verified by
examination of the 28S and 18S ribosomal bands of ethidium
bromide stained material under ultraviolet light. RNA was then
transferred onto nylon filters (Hybond-N; Amersham, Bucks, UK)
by capillary action and fixed by ultraviolet irradiation.
Filters were hybridized with a 985 bp cDNA probe coding for
rat TGF-131 (gift of Dr. Qian, NIH, Bethesda, MD, USA) and a
600 bp cDNA coding for c1 chain of type IV collagen [al(IV)]
(gift of Dr. R. Timpl, Martinsried, Germany) labeled with [a-32P]
dCTP by random primed DNA synthesis (Boehringer Mannheim,
GmbH Mannheim, Germany). Filters were hybridized in a solu-
tion containing 1% BSA, 7% SDS, 0.5 M NaHPO4 and 1 mivi
EDTA at 65°C for 16 to 20 hours and then washed three times at
65°C for 15 minutes each in 1% SDS, 40 mtvi NaHPO4 and 1 mM
EDTA. Filters were then exposed to X-ray film with intensifying
screens (Kodak X-Omat, Eastman-Kodak, Rochester, NY, USA)
at —80°C for one to seven days. Discrepancies for RNA loading
and transfer were corrected by rehybridization with an oligonu-
cleotide probe for 18S rRNA end labeled with [a-32P] dCTP by
terminal transferase (Boehringer Mannheim). The relative inten-
sity of autoradiograms was determined by scanning laser densi-
tometly (LKB Ultroscan XL, Bromma, Sweden). Results were
expressed as the ratio of optical density of TGF-1 or al(IV)
collagen to I 8S relative to baseline control kidneys which were
arbitrarily assigned a value of 1.
In situ hybridization
The eDNA encoding for TGF-1 and a1(1V) collagen were
cloned into pBlucscript KS+ (Stratagene, La Jolla, CA, USA) and
linearized with XbaI to produce antisense probes using T7 RNA
polymerase. A sense riboprobc was generated from the TGF-pl
template, linearized with EcoRI instead of XbaI, and using T7
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Table 1. Time course of renal functional changes following subtotal nephrectomy
Weeks
Baseline Partial nephrectomy Subtotal nephrectomy
0 4 12 16 4 12 16
N 60 9 10 10 9 9 7
Body wt g 250 4 344 6' 504 22° 530 20° 276 23°" 472 16° 494 9
Kidney wtg — 0.8 0.02 1.1 0.04 1.2 0.07 1.2 0.05 2.0 0.16" 2.1 0.09"
Systolic BP mm Hg 120 1 142 5 154 6° 159 2° 180 9°" 184 8.b 186 8"
Plasma creatinine nol/liter 49 1 53 2 66 2 64 2 92 5°" 113 12a,b 126 11°""
Urinary protein mg/day 12.3 1.3 14.6 1 15.4 1 16.5 2 105.3 31° 222.8 51a,h 251.6 63a.c
Data are mean SEM.
P < 0.01 versus baseline
' P < 0.01 versus PNx at same time point
J < 0.05 versus week 4 from the same group
Table 2. Renal function at 12 weeks following subtotal nephrectomy in treated and untreated animals
-________
SHAM STNx STNx + ramipril STNx + valsartan
N 10 7 10 10
Bodywtg 477±14 406±25" 426±13" 446±11
Kidney wt g 1.5 0.1 1.6 0.1 1.5 0.1 1.7 0.1
Systolic BP mm Hg 131 3 179 10" 122 4' 135 8
Averaged systolic BP mm Hg" 120 2 173 5" 116 2 134 5f.g
Plasma creatinine mmol/liter 53 2 166 2" 78 3' 76 3
24 Hour urine protein mg/day 8.7 0.6 156.1 35•5J 57.5 20.8' 65.3 16.7'
GFR mI/mm 3.2 0.4 0.6 0.2" 1.6 0.4'" 1.8 0.3"'
Plasma renin ngAI/ml/hr" 7.2 X/± 1.1 1.4 x/-i- 14d 9.8 ></÷l.21 4.5 X/÷ 111,g
"Mean of weekly blood pressure throughout study periodh Data are expressed as mean SEM except for plasma renin which is shown as geometric mean X/-- tolerance factor
cp < 0.05; dp < 0.01 vs. sham; "P < 0.05; 'p < 0.01 vs. STNx; P < 0.05 vs. STNxR
RNA polymerase that is DNA-dependent 3' to 5' RNA polymer-
ase. Five hundred nanograms of linearized template was added to
a reaction mixture of transcription buffer (final volume 20 .d)
containing 6 mrvi dithiothreitoi, 333 jiM ATP, CTP, GTP, 12 j.LM
UTP, 100 jiCi [33P] UTP (3000 Ci/mmol, New-Dupont), 20 units
RNAsin (Boehringer-Mannheim) and 20 units RNA polymerase
(Boehringer-Mannheim). The reaction mixture was incubated at
37°C for 90 minutes following which the DNA template was
digested with 1 unit RNAse-free DNAse for 15 minutes. The
riboprobe was precipitated by ammonium acetate and ethanol
using yeast tRNA as a carrier and then reconstituted in 100 j.d of
DEPC treated water. Purified riboprobe length was adjusted to
approximately 150 bases by alkaline hydrolysis [211.
Four micrometer thick sections cut from formalin-fixed paraf-
fin-embedded kidney tissue were placed onto slides precoated
with 3-aminopropyltriethoxysilane and baked overnight at 37°C.
In situ hybridization was performed essentially as previously
described [22]. In brief, tissue sections were dewaxed and rehy-
drated in graded ethanol and milliQ water, equilibrated in P
buffer (50 mM Tris-HCI, pH 7.5, 5 mst EDTA) and incubated in
125 jig/mI Pronase E in P buffer for 10 minutes at 37°C. Sections
were then washed in 0.1 M sodium phosphate buffer (pH 7.2),
briefly refixed in 4% paraformaldehyde for 10 minutes, rinsed in
milliQ water, dehydrated in 70% ethanol and air dried.
Hybridization buffer containing 2 X iO cpm/jil riboprobe in
300 mrvi NaCl, 10 mivi Tris-HCI (pH 7.5), 10 mi Na2HPO4, 5 mM
EDTA (pH 8.0), lx Denhardt's solution, 50% formamide, 17
mg/mi yeast RNA, 10% wt/vol dextran sulfate was heated to 85°C
for five minutes. Twenty-five microliters of this solution were then
added to each section. Hybridization was performed overnight at
60°C in 50% formamide humidified chambers. Sections hybrid-
ized with sense probes for TGF-f31 and al(IV) collagen were used
as controls for nonspecific binding.
After hybridization, slides were washed in 2 x SSC containing
50% formamide prewarmed to 50°C to remove coversiips. Sec-
tions were then washed in the above solution for one hour at 55°C,
rinsed three more times in RNAse buffer (10 mvi Tris-HCI, pH
7.5, 1 msi EDTA, pH 8.0, 0.5 M NaC1) and then incubated with
RNAse A (150 jig/ml) for one hour at 37°C. Sections were later
washed in 2 >< SSC for 45 minutes at 55°C, dehydrated in graded
ethanol, air dried and exposed to Kodak X-Omat autoradio-
graphic film for one to three days. Slides were then dipped in
Ilford K.5 nuclear emulsion (liford, Mobberley, Cheshire, UK),
stored in a light-free box with desiccant at room temperature for
two to three weeks, immersed in Kodak D19 developer, fixed in
Ilford Hypan and stained with hematoxylin and eosin. Gene
expression for TGF-131 and al(IV) collagen was analyzed on
autoradiograms from each animal using a Micro Computer Im-
aging Device (MCID; Imaging Research, Ontario, Canada) [23]
in accordance with guidelines for computer-assisted densitometric
quantitative autoradiography for in situ hybridization with 33P
[24]. In addition to quantitation of kidney gene expression,
localization and relative abundance of transcript were determined
using pseudocolorized computer images.
Combined in situ hybridization and immunohistochemistiy
To determine whether EDI stained monocytes/macrophages
expressed TGF-131 in the interstitium, representative sections
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Table 3. Time course of renal Structure following subtotal nephrectomy
Weeks
Baseline Partial nephrectomy Subtotal nephrectomy
—__________
0 4 12 16 4 12 16
N 60 9 10 10 9 9 7
Glomerulosclerosis 0 0 0.05 (0.02—0.08) 0.02 (0—0.06) 0.4 (0.1—0.7)"" 1.1 (O.4_1.5)c 1.06 (0.6—1.1)"'"
score
Normal tubules % 85 (83—86) 81 (78—83) 80 (76—81) 84 (82—86) 69 (49—73)"" 43 (33—72)"'" 40 (37_52)ac
Dilated tubules % 0 0.7 (0—2.1) 0.3 (0—1.0) 0.3 (0—1.0) 8.1 (5.7—14.3)"" 18.7 (6.3_21.0)""
Atrophic tubules % 0 0 0 0 0 (0_1.8)" 1.7 (0.7—7.6)""
14.9 (12.3—23.0)""
4.5 (2.4—5.2)"'"
Casts % 0 0 0 0 0(0—0.7) 0.3 (0_0.8)c
Cell infiltrates % 1.7 (1.5—2.1) 2.2 (1.5—2.5) 2.1 (1.5—2.8) 1.9 (1.6—2.0) 2.8 (2.1—6.0)" 6.5 (2.6—10.5)""
2.6 (1.6—3.2)"
7.3 (5.6—9.3)""
Interstitial fibrosis % 0 0 0 (0—0.2) 0 0 (0—5.3)" 4.5 (2.4—9.1)''" 6.8 (3.9—7.9)''"
Interstitial space % 8.6 (8.3—11.2) 11.2 (10.6—12.1) 11.4 (9.6—12.8) 10.3 (9.1—11.1) 15.6 (14.2—23.1)"" 27.4 (14.1—31.10)"'" 27.2 (24.9—28.1)"""
Data are shown as median (25th—75th percentile).
a P < 0.05 vs. baseline
hp < 0.05, "P < 0.01 vs. PNx at the same time point
"P < 0.05 vs. week 4
Table 4. Renal structure at 12 weeks following subtotal nephrectomy in treated and untreated animals
SHAM STNx STNx + ramipril STNx + valsartan
N 10 7 10 10
Glomerulosclerosis Score 0.1 (0.1—0.2) 0.9(0.8—1.0)" 0.2 (0.1—0.3)" 0.2 (0.2—0.3)"'
Normal tubules % 82.7 (79.9—84.0) 49.3 (30.4_59.3)a 79.0 (64.3—82.6)"
Dilated tubules % 0 (0—0.4) 14.4 (9.6—23.1)" 1.4 (0.3—6.1)""
Atrophic tubules % 0 (0—0) 4.1 (3.2—8.5)" 0.1 (0—0.8)"
75.7 (65.3—86.0)"
2.6 (0—3.7)"
0.7 (0_2.3r.c
Casts % 0 (0—0) 0.5 (0—2.9)" 0 (0—0)"
Cell infiltration % 1.0 (0.4—1.2) 9.8 (7.8—11.0)" 2.6 (1.9—4.3)"'"
Interstitial fibrosis % 0 (0—0) 5.5 (2.8—9.3)" 0.8 (0.2—2.3)"'"
0 (0—0.5)
4.6 (2.0—5.0)"'"
0.9 (0.2—2.3)
Interstitial space % 11.3(10.0—14.4) 27.0 (19.0—27.6)" 13.1 (11.7—19.3)" 15.0 (7.8—18.6)"
Data are shown as median (25th—75th percentile).
"P < 0.05, P < 0.01 vs. SHAM; "P < 0.05, "P < 0.01 vs. STNx
from the STNx group were examined using immunohistochemical
staining for EDI following in situ hybridization. In brief, after in
situ hybridization for TGF-131 mRNA was performed, sections
were subsequently microwave oven treated [25] and stained with
EDI antibody using the indirect avidin-biotin-complex method as
described above.
Statistics
Results are expressed as mean SEM unless stated otherwise.
Functional data were analyzed by ANOVA. Data derived from
histological studies and Northern blots were not normally distrib-
uted and were therefore analyzed by nonparametric methods: the
Mann-Whitney U-test in experiment 1 (2 groups) and Kruskal-
Wallis test in experiment 2 (4 groups). All analyses were per-
formed using the Statview SE+ Graphics package (Abacus Con-
cepts, Calabasas, CA, USA) on an Apple Macintosh Quadra 605
(Apple Computer Inc., Cupertino, CA, USA). A P value < 0.05
was considered statistically significant.
Results
Renal function
Experiment 1, Functional data are shown in Table 1. Five rats
from the STNx and one rat from the PNx group died during the
study period. Substantial weight loss was noted one week follow-
ing STNx. From the second week onward, rats that had undergone
STNx started to gain weight, though this was less evident than in
PNx rats. At each time point the remnant kidney weight was
significantly greater in STNx compared with PNx rats, presumably
reflecting compensatory renal enlargement in the former groups.
Rats that had undergone STNx became hypertensive and devel-
oped chronic renal impairment characterized by decline in GFR,
elevated plasma urea and creatinine and heavy proteinuria.
Experiment 2. Three rats from the untreated STNx group died
during the study period. Hypertension in STNx rats was amelio-
rated greatly by ramipril and to a lesser extent by valsartan when
averaged for the study period with levels of blood pressure
approaching those found in sham operated controls (Table 2).
Similarly, proteinuria and reduced GFR were improved to similar
degrees by treatment with both ramipril and valsartan (Table 2).
Blockade of the RAS by both drugs was confirmed by elevation of
plasma renin activity in these two groups compared with un-
treated STNx rats (Table 2).
Histopathology
Experiment 1. By four weeks a greater proportion of glomeruli
displayed sclerotic changes in the STNx compared with PNx group
(Table 3). The magnitude of the difference between the two
groups persisted at later time points with a further increase in the
severity of glomeruloscierosis in the STNx group. Kidneys from
STNx rats also demonstrated a variety of histopathological
changes in the tubulointerstitium that are summarized in Table 3.
The proportion of normal tubules were substantially reduced in
Fig. I. Rejiol nwnonie/;nucrophage iflfilfra000. Kidney sections w Cr'
aniined 'v immunoperoxidase technique with anti-EDt antibody. Re
Sentative sections are shown From A sliani operated controls (mat
cation 5<21)0). (B) glonierulus from SiNs (magnification 5<200).
Lubuloincerstitium rrom STN (magnification 2llU). ( D) ST Ns tre
with rarnipril (magnification 5<200). (E) STNx treated with vals
(magnification 5<20(I). Antibody stained colts (brown) arc found in si
cant numt'cr only in urnrcMcd SINs.
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Table 5. Renal monocyte/macrophage infiltration at 12 weeks following subtotal nephrectomy in treated and untreated animals
EDI cells SHAM STNx STNx + ramipril STNx + valsartan
N/glomerulus
P/01mm2 tubulointerstitium
0.03 0.01
0.73 0.07
3.73 0.24a
25.68 1.41
0.41 0.OD
1.65 045h
0.47 0.14k'
2.30 0•45b
Data are shown as mean SCM.
'P < 0.01 vs. SHAM; hp < 0.01 vs. STNx
i . 1. nal mo cyte/macrophage infiltr tion. i  ti  were ex-
amined by immunoperoxidase technique with anti-ED1 antibody. Repre-
sentative sections are shown from (A) sham operated controls ( agnifi-
cation X200), (B) glomerulus from STNx (magnification X200), (C)
tubulointerstitium from STNx ( agnification X200), ( ) S x treated
ith ramipril ( agnification x200), (E) STNx treated with valsartan
(magnification X200). Antibody stained cells (brown) are found in signif-
i t u bers   nt eated ST x.
the STNx group as a result of tubular dilatation, tubular atrophy
and interstitial pathology. Morphological features of the tubulo-
interstitial pathology increased throughout the study period in the
STNx group such that by week 16 the overall interstitial space had
expanded to 27% in the STNx group compared to 10% in the PNx
group (P < 0.01).
Experiment 2. When compared with untreated STNx animals,
administration of ramipril and valsartan significantly reduced both
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Table 6. Time course of TGF-f31 gene expression following subtotal nephrectomy as assessed by Northern analysis
Group
Weeks
Control
0
Partial nephrectomy Subtotal nephrectomy
4 12 16
—
4 12 16
N 60 9 10 10 9 9 7
TGF-pl mRNA (AU) 1.0 (0.4—1.9) 1.6 (1.4—1.9) 1.7 (1.4—2.1) 1.7 (0.9—2.4) 3.0 (2.O—3.5y°' 5.0 (2.5—5.3)' 3.5 (2.2_4.4yLh
Data are shown as median (25th—75th percentile) of the ratio of optical density for TGF-J31 mRNA to that of 18S rRNA.
ap < 0.01 vs. control
'P < 0.05, C P < 0.01 vs. partial nephrectomy at same time point
Weeks 0 4
glomerular and tubulointerstitial injury to a similar degree (Table
4). Indeed, the extent of histological injury in treated STNx rats
was similar to that found in sham-operated control animals.
Immunohistochemistiy with anti-ED 1 antibody revealed only
occassional positively stained mononuclear cells. In contrast, a
significant infiltration of stained monocytes/macrophage cells was
present in glomeruli and interstitium in STNx rats. This infiltrate
was greatly reduced and to a similar extent by both drug treat-
ments (Table 5 and Fig. 1).
Northern analysis
Experiment 1. At week 4, TGF-pl gene expression was 3.0-fold
greater in STNx compared with baseline control (week 0, P <
0.01) and 1.8 0.2-fold greater than PNx (P < 0.05) at the same
time point. This increase in TGF-f31 mRNA persisted throughout
the entire study period, while in PNx the changes in the gene
expression were not significantly different from baseline control
(P < 0.001, STNx vs. PNx; Table 6 and Fig. 2).
Experiment 2. Both ramipril and valsartan significantly reduced
overexpression of mRNA for TGF-f1 and al(IV) collagen (Table
7A and Fig. 3). Similar results were obtained when gene expres-
sion was quantitated by Northern blot using scanning laser
2.5 kb
Fig. 2. Northern blot of kidney rnRNA for TGF-
/31 at baseline and following partial (PNx) and
subtotal (STNx) nephrectomy. Increased gene
expression of TGF-/31 is seen following STNx
with no significant change in 18S rRNA.
densitometry and following in situ hybridization by MCID analysis
(Table 7B).
In situ hybridization
Kidneys from sham operated control and PNx rats demon-
strated a similar pattern of TGF-/31 gene expression with sparse
mRNA in glomeruli and tubulointerstitium (Figs. 4 and 5). In
STNx, abundant TGF-/31 mRNA was found throughout the
kidney, particularly in the pen-infarct region and cortex (Fig. 6).
Light microscopy revealed increased TGF-/31 mRNA within
glomeruli (Fig. 4) and in foci of ED1-staining inflammatory cell
infiltrates in the interstitium, predominantly in pen-tubular cells
surrounding dilated (Fig. 7) and atrophic tubules. The localization
of TGF-f31 mRNA to the latter was confirmed by positive staining
with the monocyte/macrophage-specific ED1 antibody (Fig. 7). In
contrast to STNx, this increased TGF-131 mRNA expression was
greatly reduced in association with preservation of the renal
architecture in rats whether treated with ramipril or valsartan
(Figs. 4 and 5), despite the presence of TGF-f31 mRNA in
pen-infarct areas (Fig. 6).
Groups Control STNx PNx STNx PNx STNx PNx
TGF-131
18S rRNA
12 16
1.9kb
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Table 7A. TGF-pl and csl(IV) collagen gene expression at 12 weeks following subtotal nephrectomy in treated and untreated animals as assessed
by Northern analysis
SHAM STNx STNx + ramipril STNx + valsartan
TGF-j31 mRNA (AU)
csl(IV) collagen mRNA (AU)
1.0 (0.8—1.3)
1.0 (0.7—1.5)
2.5 (2.2_2.8)a
4 (3.2_6.5)C
1.9 (1.2—2.2)'
2.6 (1.8—2.7y''
1.4 (l.3—2.3)'
2.8 (2.4_5.7)a.
Data are shown as median (25th—75th percentile) of the ratio of optical density for TGF-13l and al(IV) collagen mRNA to that of 18S rRNA.
ap < 0.01 vs. SHAM
h P < 0.05 vs. STNx; P = 0.08 vs. STNx
Table 7B. TGF-131 and al(IV) collagen gene expression at 12 weeks following subtotal nephrectomy in treated and untreated animals as assessed
by quantitative densitometry of in Situ hybridization autoradiographs
SHAM STNx STNx + ramipril STNx + valsartan
TGF-f31 mRNA (AU)
ai(IV) collagen mRNA (AU)
1.0 (1.0—1.1)
1.0 (0.9—1.0)
2.2 (2.0_2.5)a
2.9 (2.8—3.2)
1.2 (1.1—1.2)'
1.2 (1.1_1.3)l
1.3 (1.1_1.3)'
1.2 (l.1—1.6)'
Data are shown as median (25th—75th percentile) of the ratio of optical density for TGF-j31 and al(IV) collagen mRNA.
P < 0.05 vs. SHAM; bp < 0.01 vs. STNx
In sham-operated control animals the pattern of al(IV) colla-
gen gene expression was similar to that found with TGF-J31 (Figs.
8, 9 and 10). STNx rats displayed a markedly enhanced al(IV)
collagen mRNA labeling in glomeruli and in areas of tubuloin-
terstitial injury (Figs. 8 and 9). In contrast to TGF-pl, increased
mRNA for al(IV) collagen was predominantly expressed within
the tubular epithelial cells of atrophic or dilated tubules (Fig. 9).
Treatment with both ramipril and valsartan blunted the increase
in gene expression of al(JV) collagen following STNx (Figs. 8 to
10).
Discussion
The pathology that follows reduction of renal mass by subtotal
nephrectomy illustrates the relationship between altered nephron
hemodynamics and chronic renal injury [7]. The present study
demonstrates that subtotal nephrectomy is associated with over-
expression of TGF-pl and al(IV) collagen mRNA in addition to
glomerulosclerosis, tubulointerstitial fibrosis, mononuclear cell
infiltration and progressive renal impairment. Interruption of the
renin-angiotensin system by either ACE inhibition or AT1 recep-
tor blockade resulted in amelioration of TGF-f31 and al(IV)
collagen overexpression, as well as the structural and functional
abnormalities associated with subtotal nephrectomy. These find-
ings implicate an intrarenal renin-angiotensin-TGF- axis in the
pathogenesis of hemodynamically-mediated renal injury.
The role of TGF-/3 in the regulation of renal response to injury
has been studied extensively and is the subject of several recent
excellent reviews [2, 3, 26]. TGF-13 influences ECM in several ways
including increased ECM synthesis, decreased ECM degradation
and modulation of the interaction between ECM and neighboring
cells, In the kidney both TGF-/3 mRNA and protein are found in
the glomerulus and throughout the nephron [27, 28]. There is
substantial evidence to support a pathogenetic role for TGF-13 in
orchestrating the accumulation of ECM, leading to fibrosis and
renal dysfunction in several models of experimental glomerular
injury and in human kidney disease [27—32]. Renal tubulointersti-
tial injury has been studied somewhat less extensively than
glomerular disease though TGF-131 has been recently implicated
in the pathogenesis of non-hemodynamic, non-immune mediated
models of interstitial renal injury as occurs with ureteric obstruc-
tion [33], diabetic [34] and adriamycin nephropathy [35]. In
contrast to the increase in TGF-f3 expression found in progressive
kidney disease, studies of compensatory renal hypertrophy follow-
ing unilateral nephrectomy have shown either no change in
TGF-/3 mRNA and protein [36] or a reduction in TGF-f3 activity
[37].
In the present study, STNx was associated with a marked
increase in TGF-131 gene expression accompanied by glomerular
and tubulointerstitial sclerosis. In situ hybridization demonstrated
enhanced TGF-pl mRNA throughout the glomeruli and tubu-
lointerstitium. Although TGF-/31 protein was not directly mea-
sured, an increase in the biological activity of this cytokine is
supported by the concomitant increase in al(IV) collagen. In
addition, preliminary studies in a similar model have confirmed
increased TGF-j3 protein in the kidney [38]. The mechanisms that
initiate the increase in TGF-p synthesis are not well understood,
but may include mechanical factors [39] and the renin-angiotensin
system [40]. The interrelation of these factors is exemplified by the
effect of low protein diet in reducing intraglomerular hypertension
[41], renin gene expression [42] and TGF-J3 synthesis [43]. Ele-
vated blood pressure may modulate TGF-/3 production with
studies in hypertensive DOCA/salt [44] and spontaneously hyper-
tensive rats [45] displaying increased TGF-f31 in kidney and in
vascular smooth muscle cells [46]. Following STNx the resultant
elevated intraglomerular pressure, flow [7] and mechanical forces
may directly lead to activation of components of the intarenal
RAS [47] and thereby increased TGF-f3. The findings in the
present study suggest that the detrimental effects of glomerular
hypertension may be mediated by TGF-/31 [30], as has been
hypothesized in the diabetic kidney where raised intraglomerular
pressure is also associated with progressive glomerulosclerosis [7].
The mechanisms by which dynamic forces modulate TGF-f3
synthesis have been studied in mesangial cells [48] where mechan-
ical stretch has been shown to increase TGF-13 synthesis possibly
by way of ECM-integrin interactions [49, 50] and increased
angiotensin II (Ang II) [40]. Indeed, the beneficial effects of ACE
inhibition and AT1 receptor blockade demonstrated in the
present study may reflect a combination of actions that include
reduction of intraglomerular pressure, stretch and angiotensin
lI-induced augmentation of TGF-pl expression.
Reduction in renal mass is associated with complex alterations
in the intrarenal RAS in the absence of significant changes in its
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A Sham STNx STNxR STNxV
TGF-31 2.5 kb
18S rRNA 1.9kb
B x T x T x
Type IV collagen
______ 6.8kb
18S rRNA 1.9kb
Fig. 3. Northern blot of kidney mRNA for TGF-
/31 (A) and nl(IV) collagen (B) in sham
operated controls, STNx, STNx with ramipril and
STNx with valsartan. Increased gene expression
of TGF-/31 and al(IV) collagen are seen
following STNx with lesser increases in rats
treated with ramipril and valsartan. The 18S
rRNA is similar in all study groups.
Fig. 4. In situ hybridization for TGF-/31 mRNA in glomendi from (A) negative control using a sense probe, (B) sham operated controls, (C) STNx, (D) STNx
with ramipril and (E) STNx with valsartan. Abundant signal is present in kidneys from STNx rats compared with sham operated controls and STNx
animals treated with ramipril and valsartan (magnification <400).
Fig. 7. In situ hybridization of TGF-j31 mRNA in area of mononuclear cell infiltration surrounding dilated tubules in untreated STNx rat (A). Similar areas
of cell infiltration demonstrating positive staining with anti-EDI antibody by immunoperoxidase (B) (magnification X400). Combined in Situ
hybridization and immunohistochemical staining localized TGF-/31 mRNA to ED1 positive monocytes/macrophages (C) (magnification X 1000).
Publication of these figures in color was made possible by a grant from Novartis Pharmaceutical, Sydney, Australia.
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Fig. 8. In situ hybridization for al (IV) collagen mRNA in glomendi from (A) sham operated controls, (B) STNx, (C) STNx with ramipril and (D) STNx with
valsartan. Abundant signal is present in glomeruli from STNx rats compared with sham operated controls and STNx animals treated with ramipril and
valsartan (magnification )<400).
systemic counterpart [51]. Following subtotal nephrectomy
intraglomerular renin synthesis and storage is increased in
glomeruli [52] and areas adjacent to the site of infarction [53].
Similarly, TGF-131 has been localized to the pen-infarct scar
and adjacent region at eight days following STNx [54, 55]. The
findings in the present study suggest that in the long term the
progressively damaging effects of glomerular hyperfiltration,
hypertension and widespread tubulointerstitial mononuclear
cell infiltration, and possibly diffusion of Ang II [56] and other
factors, are associated with a more generalized pattern of
TGF-J3 expression.
While systemic and intraglomerular hypertension accompany
subtotal nephrectomy and many other types of chronic renal
disease, ACE inhibition and Ang II receptor blockade may confer
benefits in addition to their ability to lower systemic blood
pressure with recent evidence supporting the role of the intrarenal
RAS in the pathogenesis of non-hemodynamic renal injury. In
vitro, studies in cultured mesangial cells have shown that Ang II
stimulates ECM synthesis [40, 57], an effect that is at least in part
mediated by TGF-/3 dependent mechanisms [40]. In vivo, the role
of the RAS in non-hemodynamic kidney disease has been inferred
from the beneficial effects of ACE inhibition and Ang II receptor
blockade. For instance, the extent of tubulointerstitial fibrosis
following chronic aminonucleoside nephrosis [58] and unilateral
ureteric obstruction [15] is reduced by ACE inhibition and AT1
receptor blockade in association with a reduction of TGF-13
expression [59]. Similar findings have been recently reported in
immune complex nephritis with the ACE inhibitor, quinapril
Fig. 5. In situ hybridization for TGF-f31 mRNA in tubulointerstitium from (A) sham operated controls, (B) STNx, (C) STNx with ramipril and (D) STNx
with valsartan. Abundant signal is present in kidneys from STNx rats compared with sham operated controls and STNx animals treated with ramipril
and valsartan (magnification ><200).
Fig. 6. In situ hybridization for TGF-/3] mRNA in autoradiograph showing distribution and intensity of transcript in (A) sham operated controls, (B) STNx,
(C) STNx with ramipril and (D) STNx with valsartan. Magnitude of gene expression is indicated semiquantitatively in pseudocolorized computer image
(blue-nil, green-low, yellow-moderate). Abundant TGF-/31 mRNA was present in the pen-infarct scar (lower region) of all STNx kidneys. Kidneys from
untreated STNx rats also displayed abundant cortical signal when compared with sham operated controls and treated STNx rats (magnification X4).
Publication of these figures in color was made possible by a grant from Novartis Pharmaceutical, Sydney, Australia.
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Fig. 9. In situ hybridization for cii (I V) collagen mRNA in tubulointerstitium
from (A) sham operated controls (magnification X200), (B) STNx (magni-
fication ><200), (C) STNx (magnification X400), (D) STNx with ramipril
(magnification x200) and (E) STNx with valsartan (magnification X200).
Abundant signal is present in the tubular epithelium of kidneys from STNx
rats compared with sham operated controls and STNx animals treated
with ramipril and valsartan (magnification X400).
which reduced TGF-p overexpression as well as structural and
functional abnormalities in the absence of an effect on blood
pressure [60].
In many primary glomerular diseases the extent of interstitial
damage correlates more closely with the degree of renal dysfunc-
tion than do indices of glomerular injury [61, 621, and the
mechanisms by which such glomerular changes lead to tubuloin-
terstitial injury has been the focus of considerable recent attention
[63—65]. Growth factors produced in the glomerulus may affect
tubulointerstitial changes by both direct and indirect means. For
instance, growth factors may reach the tubulointerstitium by
passing through the nephron with the glomerular ultrafiltrate or
by the peritubular capillary network. Alternatively, growth factors
may be produced locally within the tubulointerstitium. Cell types
that are candidates for mediating tuhulointerstitial injury in
association with glomerular disease are infiltrating mononuclear
cells, tubular epithelial cells and resident interstitial fibroblasts.
Angiotensin converting enzyme is present in both fibroblasts [66]
and monocytes. Indeed, transformation of the latter into mac-
rophags is associated with increased ACE activity [67]. Studies
from Egido suggest that Ang II may stimulate renal interstitial
cells to proliferate and increase ECM synthesis [681. Infusion of
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Fig. 10. In situ hybridization for al(IV) collagen mRNA in autoradiograph showing distribution and intensity of transcript in (A) sham operated controls,
(B) STNx, (C) STNx with ramipril and (D) STNx with valsartan. Magnitude of gene expression is indicated semiquantitatively in pseudocolorized
computer image (blue-nil, green-low, yellow-moderate, red-high). High signal intensity indicating abundant csl(IV) collagen mRNA was present in the
pen-infarct scar (lower region) of all STNx kidneys. Kidneys from untreated STNx rats also displayed abundant cortical signal when compared with sham
operated controls and treated STNx rats (magnification x4). Publication of this figure in color was made possible by a grant from Novartis
Pharmaceutical, Sydney, Australia.
angiotensin II leads to glomerular and tubulointerstitial injury and
is accompanied by interstitial infiltration of monocytes/macro-
phages [69], a rich source of TGF-/3 and other fibrogenic cytokines
[70]. Indeed, as a consequence of its endocrine, paracrine and
autocrine actions [71] increased glomerular TGF-13 may induce
TGF-f3 synthesis in the tubulointerstitium, thereby leading to
further monocyte-macrophage infiltration ECM synthesis and
fibrosis. Thus, following subtotal nephrectomy activation of the
RAS in glomeruli and pen-infarct areas may lead to widespread
glomerulosclerosis, tubulointerstitial fibrosis and mononuclear
cell infiltration. The findings in the present study of amelioration
of all these pathological features by ACE inhibition and AT1
receptor blockade in association with reduced TGF-pl gene
expression support a role for an intrarenal renin—angiotensin-—-
TGF-p axis in the pathogenesis of injury following renal mass
reduction. Our findings implicate infiltrating mononuclear cells as
a source of interstital TGF-p, which may then stimulate fibrogen-
esis by interstitial fibroblasts. In addition, TGF-13 expression was
present in the tubular epithelium (albeit to a lesser extent than in
peritubular cells), suggesting that these cells may also contribute
to tubulointerstitial fibrosis following STNx.
Pharmacologically the effects of ACE inhibition and AT1
receptor blockade are different. In addition to angiotensin I,
substrates for angiotensin converting enzyme include bradykinin,
substance P and neurokinins, peptides which may be involved in
both the beneficial and adverse effects of ACE inhibitors [72].
Additionally, reduction in Ang II by ACE inhibition will result in
less ligand binding to AT2 receptors. In contrast, AT1 receptor
blockade may lead to an increase in available Ang II to bind to
AT2 receptors [72]. As in the present study ACE and AT1
receptor blockade have been previously shown to have similar
beneficial effects on tissue injury following subtotal nephrectomy
[9] and ureteric obstruction [15]. However, unlike the findings in
the present study, Ishidoya and colleagues reported that following
ureteric obstruction monocyte/macrophage infiltration was re-
duced by ACE inhibition, but not by AT1 receptor blockade 15].
A similar discordance in effect was also found in passive Heymann
nephritis, where losartan failed to reduce albuminuria in contrast
to the beneficial effects of enalapril [73]. While the latter findings
may reflect the nature of the disease model, further studies into
the relative importance of AT1 and AT2 receptors as well as the
other products of ACE inhibition are warranted.
In addition to sclerosis, STNx is also associated with cell
proliferation. Previous reports have documented increased plate-
let-derived growth factor (PDGF) mRNA, protein and receptor
following STNx in both glomeruli [74] and in tubulointerstitium
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[19]. This is consistent with a role for this pro-proliferative
cytokine in the induction of the mesangial and tubular cell
proliferation that occur in STNx [75]. Indeed, the latter findings in
combination with those of the present study suggest that increased
PDGF and TGF-13, respectively, may be pathogenetic factors in
the cellular proliferation and sclerosis that follow STNx, akin to
the recent description of these two cytokines as mediators of cell
proliferation and matrix expansion in human IgA nephropathy
[28]. Furthermore, an interaction between these two growth
factors is possible given the ability of TGF-3 to induce PDGF
production in vitro [76]. However, the role of RAS in regulating
PDGF synthesis and action remains to be determined.
In summary, STNx in rats is associated with profound glomer-
ular and tubulointerstitial changes that accompany proteinuria,
hypertension and renal impairment. STNx was associated with a
marked increase in gene transcription of TGF-131 in both glomer-
uli and in the tubulointerstitium. This overexpression of TGF-f31
was ameliorated by both ramipril and valsartan. These findings
suggest that TGF-f31 may mediate aspects of the injury that follow
reduction in renal mass. Furthermore, the beneficial effects of
ACE inhibition and AT1 receptor blockade may, at least in part,
be due to a reduction in TGF-/31 expression.
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Abbreviations used in this paper are: TGF-I3, transforming growth
factor-p; Ang II, angiotensin II; AT1, type 1 angiotensin II receptor;
ECM, extracellular matrix; al(IV) collagen, ol chain of type IV collagen;
RAS, renin-angiotensin system; STNx, subtotal nephrectomy; PNx, partial
nephrectomy.
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